Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Fiduciary Group LLC

Fiduciary Group LLC decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 13.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,712 shares of the company’s stock after selling 1,000 shares during the period. Fiduciary Group LLC’s holdings in Henry Schein were worth $464,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HSIC. Versant Capital Management Inc boosted its stake in shares of Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $32,000 after acquiring an additional 335 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock valued at $41,000 after acquiring an additional 569 shares during the last quarter. Quent Capital LLC boosted its stake in shares of Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after acquiring an additional 323 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Henry Schein by 23.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after acquiring an additional 143 shares during the last quarter. Finally, City State Bank acquired a new stake in shares of Henry Schein during the fourth quarter valued at $55,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Activity at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Henry Schein stock opened at $70.45 on Friday. The stock’s 50-day moving average is $74.83 and its 200-day moving average is $72.61. The company has a market cap of $8.75 billion, a price-to-earnings ratio of 28.99, a price-to-earnings-growth ratio of 2.13 and a beta of 0.90. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.49.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 earnings per share. Equities analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Jefferies Financial Group increased their target price on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Wells Fargo & Company assumed coverage on Henry Schein in a research report on Friday, February 14th. They set an “equal weight” rating and a $80.00 target price on the stock. Barrington Research reiterated an “outperform” rating and set a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and increased their target price for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, UBS Group reduced their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Henry Schein has an average rating of “Moderate Buy” and a consensus price target of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.